Piramal Enterprises Ltd. (PEL) is the flagship company of Piramal Group and has a leading position in the business verticals it is present in i.e. Healthcare and Financial Services.
In the late 1980s, they moved from textile to pharmaceuticals. While others were keen over international generics, they invested in the domestic formulation development business. The efforts soon bore returns as they have had a track record of approx. 23% revenue CAGR since then. In 2010, it completed sale of its domestic formulations business an unprecedented value of ~9x sales and ~30x EBITDA. In May 2013, Piramal Enterprises Ltd. acquired 10% equity stake in Shriram Transport Finance. Later in April 2014, they acquired 20% equity stake in Shriram Capital Limited, a financial services company and in June 2014, 9.9% stake in Shriram City Union Finance Limited, the retail focused Non-banking Financial Company (NBFC) of the Shriram Group.
Driven by the values and propelled by strong governance, they have built an expansive team and a wide network through partnerships with esteemed companies.
The Piramal Group, a US$4bn diversified global business conglomerate, has operations in over 30 countries and brand-presence across 100 markets around the world. Piramal Enterprises Ltd. (PEL), the Group's flagship company, has a leading position in all the business verticals it is present in - Healthcare, Information Management and Financial Services. PEL’s consolidated revenues was $830mn in FY2015, with approx. 70% of revenues from outside India.
Pharma Solution division of PEL is a global leader in contract development and manufacturing. Critical Care division is one of the three players globally and the only company in the world with the complete inhalation anesthetic product portfolio of all 5 gases. OTC division has a wide portfolio including brands such as LactoCalamine, i-range, Saridon, Polycrol, Jungle Magic etc.
The Imaging business includes rights to Florbetaben (NeuraCeqTM), a highly specialized molecule used in PET imaging to detect Beta-amyloid plaque; it has received approval to commercially market in EU and the US. Bio-Orthopaedics division has a product BST-CarGel®, a novel bioscaffold for advanced cartilage regeneration. It has been commercially launched in Europe.
The financial services vertical is broadly divided into 2 entities – Piramal Fund Management (PFM) and Structured Investment Group (SIG). PFM, an integrated entity (private equity & nbfc), provides exposure to real estate across the entire capital stack i.e. private equity, structured / mezzanine equity, structured debt, senior secured debt and construction finance. The SIG division provides structured mezzanine funding to corporate's in various sectors including infrastructure.
PEL’s information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry, providing high quality, web-enabled research, predictive analytics via proprietary databases and consulting services to the global healthcare industry.
Where is Piramal Enterprises Ltd. (PEL)